tiprankstipranks
Trending News
More News >
Anika Therapeutics (ANIK)
NASDAQ:ANIK
Advertisement

Anika Therapeutics (ANIK) Stock Statistics & Valuation Metrics

Compare
163 Followers

Total Valuation

Anika Therapeutics has a market cap or net worth of $162.20M. The enterprise value is $129.82M.
Market Cap$162.20M
Enterprise Value$129.82M

Share Statistics

Anika Therapeutics has 14,341,423 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14,341,423
Owned by Insiders4.28%
Owned by Institutions42.63%

Financial Efficiency

Anika Therapeutics’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -8.98%.
Return on Equity (ROE)-0.37
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-8.98%
Return on Capital Employed (ROCE)-0.03
Revenue Per Employee416.34K
Profits Per Employee-195.78K
Employee Count288
Asset Turnover0.59
Inventory Turnover1.84

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio
PS Ratio0.00
PB Ratio1.06
Price to Fair Value1.57
Price to FCF-47.25
Price to Operating Cash Flow29.23
PEG Ratio3.57

Income Statement

In the last 12 months, Anika Therapeutics had revenue of 119.91M and earned -56.38M in profits. Earnings per share was -3.83.
Revenue119.91M
Gross Profit76.00M
Operating Income-5.10M
Pretax Income-2.76M
Net Income-56.38M
EBITDA3.02M
Earnings Per Share (EPS)-3.83

Cash Flow

In the last 12 months, operating cash flow was 5.40M and capital expenditures -8.75M, giving a free cash flow of -3.35M billion.
Operating Cash Flow5.40M
Free Cash Flow-3.35M
Free Cash Flow per Share-0.23

Dividends & Yields

Anika Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.89
52-Week Price Change-58.78%
50-Day Moving Average11.26
200-Day Moving Average15.72
Relative Strength Index (RSI)53.58
Average Volume (3m)103.38K

Important Dates

Anika Therapeutics upcoming earnings date is Jul 30, 2025, After Close (Confirmed).
Last Earnings DateMay 9, 2025
Next Earnings DateJul 30, 2025
Ex-Dividend Date

Financial Position

Anika Therapeutics as a current ratio of 4.88, with Debt / Equity ratio of 17.14%
Current Ratio4.88
Quick Ratio3.85
Debt to Market Cap0.10
Net Debt to EBITDA-9.83
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Anika Therapeutics has paid 6.06M in taxes.
Income Tax6.06M
Effective Tax Rate-2.19

Enterprise Valuation

Anika Therapeutics EV to EBITDA ratio is 70.40, with an EV/FCF ratio of -91.21.
EV to Sales1.77
EV to EBITDA70.40
EV to Free Cash Flow-91.21
EV to Operating Cash Flow39.35

Balance Sheet

Anika Therapeutics has $53.37M in cash and marketable securities with $25.44M in debt, giving a net cash position of -$27.93M billion.
Cash & Marketable Securities$53.37M
Total Debt$25.44M
Net Cash-$27.93M
Net Cash Per Share-$1.95
Tangible Book Value Per Share$9.81

Margins

Gross margin is 62.58%, with operating margin of -4.25%, and net profit margin of -47.02%.
Gross Margin62.58%
Operating Margin-4.25%
Pretax Margin-2.31%
Net Profit Margin-47.02%
EBITDA Margin2.52%
EBIT Margin-4.25%

Analyst Forecast

The average price target for Anika Therapeutics is $21.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$21.50
Price Target Upside86.96% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-18.80%
EPS Growth Forecast26.16%

Scores

Smart Score6
AI Score47
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis